All Episodes
Oncology Learning Network — 187 episodes
Preparing for Biomarker-Directed Care in epNEC: What Pathologists Need to Know Now
Artificial Intelligence for Skin Cancer Diagnosis
Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF
Real-World Decision Points in Biomarker-Driven NSCLC Management
Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling
Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC
Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma
When to Raise the Question of CAR T–Cell Therapy in Multiple Myeloma
Closing the Gap Between CAR T–Cell Therapy Recognition and Referral in Multiple Myeloma
Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia
How is ctDNA MRD Testing Used in Lymphoma Care?
How Are We Detecting Residual Disease in Lymphoma Today?
How Are We Detecting Residual Disease in Lymphoma Today?
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG)
Navigating The Complexity of Melanoma Care: Part 6
Navigating The Complexity of Melanoma Care: Part 5
Navigating The Complexity of Melanoma Care: Part 4
Navigating The Complexity of Melanoma Care: Part 3
Navigating The Complexity of Melanoma Care: Part 2
Navigating The Complexity of Melanoma Care: Part 1
Community Education Program Improves Patient Education and Cancer Screening Rates
Cholangioscopy: What Interventional Oncologists Need to Know Part 2
Cholangioscopy: What Interventional Oncologists Need to Know
Applications of AR in Interventional Oncology
How Artificial Intelligence May Change Interventional Oncology
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
Episode 1: Maintenance Rituximab for Waldenström Macroglobulinemia
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
Advances in Gastrointestinal Genetic Testing
Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy
BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma
Durvalumab Conveys Benefit for All Biliary Tract Cancer Types
Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
Maintenance Cabozantinib in Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer
Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer
Part 1: Current Emerging Therapies for Platinum-Resistant Ovarian Malignancies With Dr O'Mally
Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML
Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL
Evolving Roles of KRAS Inhibitors in CRC
The Role of Tumor Mutation Burden Featuring Dr Morris
Dr Morris Discusses Emerging Targeted Therapies in mCRC
Dr Lieu Talks ctDNA to Guide CRC Treatment
Dr Casulo Overviews Approved Treatment Options to Manage Newly Diagnosed, Relapsed FL
Dr Batlevi Shares Promising Data of Tazemetostat from SYMPHONY-1 Trial
Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II
Dr Loprinzi Reviews Hot Flash Treatment Strategies for Patients With Breast Cancer
Dr Jacob Reviews SunRISe-1 Trial Progress in HR-NMIBC
Dr Chi, MD, Discusses Phase 3 MAGNITUDE, SPARTAN, and TITAN Study Results
Dr Melani Shares Impressive Results of the ViPOR Trial for MCL
Dr Slavin Discusses Ways to Improve PRS by Reducing Ancestral Bias in BC
Dr Mascarenhas Discusses AVID200 for Patients With Myelofibrosis
Dr Wildgust Reviews CASSIOPEIA Phase 3 Results in First-Line MM
Dr Wildgust Discusses Racial Disparities in Treatment Patterns,Outcomes in MM
Dr Williams Reviews SunRISe-2 Trial Results for Muscle-Invasive Urothelial Carcinoma
Dr Aggarwal Discusses Plasma-Based Next-Generation Sequencing for Patients with Nonsquamous NSCLC
Tapan Kadia, MD, Highlights Venetoclax Plus Chemotherapy for AML, MDS
Dr Elhassadi Highlights the Impact of a p53 Alteration in Patients With MCL
Dr Morikawa Discusses Assessing Risk of Brain Metastasis in HER2+ Breast Cancer
Talquetamab Well Tolerated in Relapsed/Refractory MM
Improvements in the Treatment of Patients With MCL Over the Past Decade
Dr Fakih Reviews Upfront Molecular Panel Testing in Metastatic GI Cancers
Holly Pederson, MD, Discusses Ancestrally Unbiased Polygenic Breast Cancer Risk Assessment
Ponatinib Dosing Regimen Demonstrates Improved Responses, Survival in Patients With CP-CML
Nirav Shah, MD, Discusses Dual-Targeted CAR T Cells for HL, CLL
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
Dr Shitara Discusses Trastuzumab Deruxtecan for Treatment in HER2-Positive Gastric Cancer
Dr Saad Highlights Results Following the ACIS Study
Andres Cervantes, MD, PhD, Discusses Trastuzamab Deruxtecan as Emerging Therapy for Gastric Cancer
Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies
Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC
Andreas Hochhaus, MD, Talks About the ASCEMBL Trial, Eliminating LSCs in CML
Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP
Noopur Raje, MD, Talks Anti-BCMA CAR-T Therapy for Relapsed/Refractory MM
Dr Leonard Shares Highlights to Expect at the 2020 Leukemia, Lymphoma & Myeloma Congress
Episode 4: Evolving Therapies in Ewing Sarcoma
Abhishek Maiti, MD, Talks 10-Day Decitabine Plus Venetoclax for Intensive Chemo–Ineligible AML
Dr Nagourney on CRC Cells Treated with FOLFOX or CAPOX
Dr Jazieh Highlights the Prevalence of ALK+ NSCLC in the Middle East and North Africa
Episode 3: Standard of Care Treatment for Ewing Sarcoma
Sarcoma Soundbites with Brian and Bob: Ewing Sarcoma, Part 1
Dr Percival on New AML Treatments
Combo of RAF/MEK Inhibitor and Defactinib Shows Promise in Patients With KRAS+ Ovarian Cancer
Veena Shankaran, MD, MS, Discusses Financial Hardships in Patients With Metastatic CRC
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Dr Jabbour on Management of Ph+ and Ph-like ALL
Christopher Crane, MD, Discusses Benefits of Long-Course Vs Short-Course RT for Rectal Cancer
CAR T-Cell Therapy Promising for Relapsed, Refractory Large B-Cell NHL
Long-term Follow Up of First-line NALIRIFOX in Pancreatic Cancer
Interim Analysis Suggests Correlation Between Ponatinib Dosing and Efficacy in CML
No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma
Faster Corticosteroid Tapering Safe in Relapsed/Refractory MM
BCMA-Directed CAR-T Therapy Shows Promise in Heavily Pretreated MM
Triplet Combo Well-Tolerated, Effective for IDH1-Mutated AML
Shirish Gadgeel, MD, Discusses Follow-Up Results of Pembrolizumab with Chemotherapy for NSCLC
COA Annual Conference Goes Virtual for 2020
Sarcoma Sound Bites with Brian and Bob: Exploring the Territory of TGCT (Part 1)
Treating Lung Cancer in the COVID-19 Climate
Impact of Text Messaging on Therapy Adherence in Patients With Breast Cancer
Improving Logistics to Encourage Patient Enrollment in Cancer Clinical Trials
Fractures and the Use of Bisphosphonates in Patients With Breast Cancer
Michiel Van de Sande, MD, Discusses Multidisciplinary Approach to Treating TGCT
Post-Transplant TKI Salvage Therapy Provides Significant Survival Benefit Following Relapse in CML
BTK Inhibitors Important in the Treatment Landscape of MCL
ACCC President Talks Community Oncology and Bridging the Research Gap
Direct-to-Patient Strategies in Multiple Myeloma Care
Kevin Kalinsky, MD, MS, Talks About the Importance of Gene-Profiling for Early-Stage Breast Cancer
Non-Chemotherapy Approach Induces High Rate of Undetectable MRD in CLL
KTE-X19 Shows Great Efficacy in Heavily Pretreated MCL
SEQUOIA Trial: No Clinical Benefit Adding Pegilodecakin to FOLFOX for Pancreatic Cancer
Matt Kalaycio, MD, Discusses the Historical Treatment of CML
Belantamab Mafodotin Demonstrates Promising Safety and Efficacy for MM
Front-Line Ibrutinib Plus Venetoclax Effective for CLL Irrespective of Patient Age
Marginal Zone Lymphoma: Biology and Treatment
Ruxolitinib-BET Inhibitor Combo Promising for Myelofibrosis
iFCG Regimen Effective for Young, Fit Patients With IGHV-Mutated CLL
Scalp Cooling Device Lowers Risk for Chemo-Related Hair Loss, Gives Patients With Cancer Control
Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML
Acalabrutinib Alone or in Combination With Obinutuzumab Improves PFS in Treatment-Naïve CLL
Pacritinib Promising for Patients With Myelofibrosis and Severe Thrombocytopenia
Mark Pegram, MD, Discusses the HER2CLIMB Trial and the Promising Nature of Tucatinib Therapy
Dr Abou-Alfa Discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer
Effect of Cost on Adherence to Therapy in Patients With Breast Cancer
Encouraging Clinical Trial Participation in Patients With Cancer
Updates in the HER2 Breast Cancer Therapy Space - Part I
Updates in the HER2 Breast Cancer Therapy Space - Part II
Shanu Modi, MD, Discusses the DESTINY-Breast01 Trial
Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma
DS-8201a Shows Promise in Treatment of HER2-Positive Breast Cancer
Treating Early Stage, HER2-Positive Breast Cancer
The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy
Evolution of the treatment landscape for Tenosynovial Giant Cell Tumors
Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors
Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer
Amer Zeidan, MBBS, MHS, discusses Myelodysplastic Syndrome(MDS)at 2019 ASH MHM
Newer Treatment Options for Patients With Hodgkin Lymphoma
Treating Newly Diagnosed Patients With MCL
FOxTROT Trial Supports Preoperative Chemotherapy in Colon Cancer, with Matthew Seymour, MD
Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma
Neratinib Plus Capecitabine Improves PFS in HER2-Positive Breast Cancer
Adding Ribociclib to Endocrine Therapy Improves OS in Young Patients With Advanced Breast Cancer
Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma
Novel Immunotherapy Approaches for Multiple Myeloma
Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma
Survey Results Show Oncologists Want to Learn More About the Needs of LGBTQ Patients
Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors
Patient Characteristics to Consider for Use of Chemotherapy for Soft-Tissue Sarcoma
Are Existing Data Reliable Enough to Support Using Chemo for Soft-Tissue Sarcoma?
Enzalutamide–ADT Combo significantly Improves PFS in Metastatic Hormone-Sensitive Prostate Cancer
“Spectacular” Trial Results Establish New Standard of Care for Advanced Kidney Cancer
Tivozanib Shows Promise Over Sorafenib in Patients With Advanced, Treatment-Refractory RCC
Survival Benefits of PARP Inhibitors in Metastatic CRPC Favor BRCA1/2 Over ATM Mutations
Great Debates in Oncology: Preview of Round 1 - Dr Trent
Practice-Changing Potential in CLL
Apalutamide Significantly Delays Metastasis in SPARTAN Trial of Nonmetastatic CRPC
New Advances in Research Pave the Way for the Treatment of Nonclear Cell RCC
Round 3: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma
Round 2: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma
CLL Novel Therapy Patterns, Dosing, and Sequencing: Results of the informCLL Real-World Registry
Gemtuzumab Ozogamicin a Safe, Tolerable Option for Patients With Relapsed/Refractory AML
Early Results Show Promise With Venetoclax-Idasanutlin Combo for Relapsed/Refractory AML
Extended Decitabine Dosing Schedule Provides No Benefit Over Shorter Regimen in Newly Diagnosed AML
The Use of CAR-T Therapy for B-Cell Lymphomas Outside of Clinical Trials
Round 1: The Use of Adjuvant And Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma
Introduction: The Use of Adjuvant/ Neoadjuvant Chemotherapy in Soft-Tissue Sarcoma
Quadruplet Therapy Yields Promising Results in Newly Diagnosed MM
Penn Medicine Looks to Improve Outcomes For Solid Tumors With CAR-T
Navigating the Treatment Landscape for Multiple Myeloma - Callander
Cost of Cancer Care in the Outpatient vs Community Oncology Setting - Lucio Gordon
The Future of CML Treatment: An Interview With Gabriela Hobbs, MD - Part 3
Jonathan Friedberg, MD, Discusses Burkitt Lymphoma
Jonathan Friedberg, MD, Discusses The Future of Treatment for Aggressive Lymphomas - Part III
John Leonard, MD, Discusses the Evolving Treatment Landscape for Mantle Cell Lymphoma - Part I
Salvage Therapies for CML: An Interview With Gabriela Hobbs, MD - Part II
Jonathan Friedberg, MD - Treatment for Aggressive Lymphoma and Clinical Implications - Part II
John Leonard, MD - Future Outlook of Mantle Cell Lymphoma Treatment - Part III
John Leonard, MD - Mantle Cell Lymphoma And Indolent Mantle Cell Lymphoma - Part II
John Leonard, MD - FL And Hematology Drugs In The Pipeline - Part IV
John Leonard, MD - Future Landscape Of FL Therapy, And Managing Survivors Of FL - Part III
John Leonard, MD - The Evolving Treatment Landscape for Follicular Lymphoma - Part I
Dr. Gail Roboz - Clinical Trials and the Future of Treatment in AML – Part III
Dr. Gail Roboz - Using Drugs Newly Approved by the FDA to Treat AML - Part II
Dr. Jonathan Friedberg - Barriers to Care in Aggressive Lymphoma - Part 1
OLN Interview With Dr. Gail Roboz - Part I
OLN Interview With Dr. Gabriela Hobbs - Part 1
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
Showalter - Decline of a "Gold-Standard" Treatment in Cervical Cancer